Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
3

Story being shared
Mesoblast's spinal treatment may enter late-stage trial this year
Mesoblast plans to launch a late-stage trial this year of NeoFuse, a mesencyhmal precursor stem cell treatment for spinal fusion, after announcing promising results from a midstage study. Patients in the Phase II trial who received 25 million mesenchymal precursor cells had higher fusion rates after 12 months than those who got bone autograft. The treatment also was associated with diminished surgical blood loss, according to the study.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .